PMID- 36312666
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 9
DP  - 2022 Sep
TI  - Durable Complete Remission With Combination of Stereotactic Body Radiation 
      Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in 
      Refractory Metastatic Melanoma.
PG  - e29573
LID - 10.7759/cureus.29573 [doi]
LID - e29573
AB  - Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical 
      scenario. We present the case of a patient who was refractory to standard of care 
      but was able to achieve a durable complete remission with the combination of 
      stereotactic body radiation therapy (SBRT), talimogene laherparepvec (TVEC), and 
      ipilimumab.
CI  - Copyright (c) 2022, Wolfe et al.
FAU - Wolfe, Zachary
AU  - Wolfe Z
AD  - Hematology and Medical Oncology, Lehigh Valley Topper Cancer Institute, 
      Allentown, USA.
FAU - Blackham, Aaron
AU  - Blackham A
AD  - Surgical Oncology, Lehigh Valley Topper Cancer Institute, Allentown, USA.
FAU - McIntosh, Alyson
AU  - McIntosh A
AD  - Radiation Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
FAU - Miller, Angela
AU  - Miller A
AD  - Hematology and Medical Oncology, Lehigh Valley Topper Cancer Institute, 
      Allentown, USA.
FAU - Sheikh, Hina
AU  - Sheikh H
AD  - Pathology, Health Network Laboratories, Allentown, USA.
FAU - Nair, Suresh
AU  - Nair S
AD  - Hematology and Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
LA  - eng
PT  - Case Reports
DEP - 20220925
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9596194
OTO - NOTNLM
OT  - immunotherapy
OT  - melanoma
OT  - oncolytic viruses
OT  - radiation therapy
OT  - targeted therapeutics
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/09/25
CRDT- 2022/10/31 04:42
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/10/31 04:42 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/09/25 00:00 [pmc-release]
AID - 10.7759/cureus.29573 [doi]
PST - epublish
SO  - Cureus. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573. eCollection 2022 
      Sep.